GlassScriptPhysician profile
Robert William Gladney
NPI 1134507007
$7,835.36
in general payments reported to CMS, 2019-2025
32 companies · $5,260 in 2025
The $5,260 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $151 · 2021: $184 · 2022: $620 · 2023: $321 · 2024: $1,187 · 2025: $5,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,800 · Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,800.00 |
| Food and Beverage | $968.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $5,800.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $339.69 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $259.44 | 2021-2025 | |
| Pfizer INC. | $176.61 | 2022-2025 | |
| Shield Therapeutics INC | $165.70 | 2022-2025 | |
| Organon LLC | $154.88 | 2021-2025 | Nexplanon |
| Millicent US INC | $151.99 | 2020-2025 | Intrarosa, Femring, Femlyv |
| Sage Therapeutics, LLC | $76.66 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $73.41 | 2023 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $69.73 | 2019-2025 | |
| Therapeuticsmd, INC. | $50.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.21 | 2019-2022 | |
| Molnlycke Health Care US, LLC | $45.85 | 2022 | |
| Scynexis, INC. | $41.29 | 2022 | |
| Supernus Pharmaceuticals, INC. | $38.30 | 2025 | Qelbree |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.66 | 2025 | Veozah |
| Exeltis, USA INC. | $30.97 | 2022 | |
| Meditrina | $30.28 | 2024 | |
| Daiichi Sankyo INC. | $25.11 | 2022 | |
| Octapharma USA, INC. | $23.37 | 2025 | Fibryga |
| Agile Therapeutics, INC. | $22.31 | 2021 | |
| Channel Medsystems, INC. | $21.50 | 2022 | |
| Evofem Biosciences, INC. | $19.40 | 2021 | |
| Becton, Dickinson and Company | $18.96 | 2023 | Bd Onclarity |
| Lundbeck LLC | $18.83 | 2022 | |
| Sumitomo Pharma America, INC. | $16.14 | 2023 | Myfembree |
| Novo Nordisk INC | $15.96 | 2025 | Wegovy |
| Integra Lifesciences Corporation | $15.34 | 2022 | |
| Mission Pharmacal Company | $14.58 | 2022 | |
| Merck Sharp & Dohme LLC | $13.93 | 2022 | |
| Convatec INC. | $13.49 | 2022 | |
| Acessa Health INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gladney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.